Comorbidity

Medically-supervised Commercial Program Delivers Nearly 15% Weight Loss at Scale

Retrieved on: 
Wednesday, November 2, 2022
General Health, Diabetes, Health, Fitness & Nutrition, Cardiology, Weight loss, The Obesity Society, Glycated hemoglobin, Health, Sleep, HDL, Overweight, Conference, Obesity, Exercise, Cancer, Research, Patient, Physician, Program, Degenerative disease, LDL, Overalls, Food, Tiger Global Management, Comorbidity, Metabolism, ILI, Founders Fund, Conditional sentence, World Obesity Day, Insulin, Diabetes, HS, Pharmaceutical industry, Medicine, Health insurance, Triglyceride, Calibration

and former World Obesity Federation President Donna Ryan, M.D., also found patients were able to sustain weight loss at 18 months.

Key Points: 
  • and former World Obesity Federation President Donna Ryan, M.D., also found patients were able to sustain weight loss at 18 months.
  • Today, nearly 200 million adults in the US qualify for obesity treatment and fewer than 1% of qualifying adults receive it.
  • The findings presented at the Obesity Society Annual Conference spotlight the far-reaching potential of commercial opportunities to provide medically-supervised treatment at scale by addressing geographic and economic inequities.
  • Through Calibrate, people can sustain long-term weight loss results after medication with a digital commercial program that combines medication with proprietary ILI.

Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

Retrieved on: 
Monday, October 24, 2022
Efficiency, The New England Journal of Medicine, NASDAQ, Acute respiratory distress syndrome, Medicine, Mortality, Zuclomifene, TGA, U.S. Securities and Exchange Commission, Tadalafil, Telehealth, Comorbidity, Infection, AR, Eli Lilly and Company, Private Securities Litigation Reform Act, WHO, Company, GLOBE, Odds ratio, FDA, Government, Hospital, MHRA, Review, Lilly, Vaccine, Security (finance), Collection, Trial of the century, Prostate cancer, Death, Flash, Form 10-Q, CDK, Insurance, Medicines and Healthcare products Regulatory Agency, Disease, Patient, Man, European Medicines Agency, Finasteride, Safety, Fast Track, Gonadotropin-releasing hormone, Forward-looking statement, Pregnancy, COVID-19, Capsule, Pharmaceutical industry, Birth control, Medical imaging, D.C, ICU, Verus Pharmaceuticals

Utilizing sabizabulin in WHO Class 4 patients may help prevent progression of disease, filling a gap in care in our hospitalized patients, said Paula Skarda, M.D.

Key Points: 
  • Utilizing sabizabulin in WHO Class 4 patients may help prevent progression of disease, filling a gap in care in our hospitalized patients, said Paula Skarda, M.D.
  • Internal Medicine/Pediatrics Regions Hospital, St. Paul, Minnesota, a lead investigator in Verus Phase 2 and Phase 3 clinical trials of sabizabulin.
  • Patients were randomized (2:1) to sabizabulin 9 mg or placebo oral daily dose (up to 21 days or discharge from hospital).
  • Randomization was stratified by oxygen requirement at baseline (WHO 4 = supplemental oxygen, WHO 5 = NIV/forced oxygen, WHO 6 = mechanical ventilation).

Real-World Evidence Solutions Global Market Report 2022: Need for Precise and Clear Information About the Safety and Efficacy of New Products Driving Adoption - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 25, 2022
Neurology, Cardiology, Biotechnology, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Real-World Evidence, Adoption, Prevalence, Vaccine, RWD, CAGR, Patient, Drug development, Cancer, Industry, Obesity, Conditional sentence, Safety, Diabetes, Comorbidity, Off-label use, RWE, COVID-19, Solution, Compliance, Pharmaceutical industry, Growth

The "Real-World Evidence Solutions Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Real-World Evidence Solutions Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global real-world evidence solutions market size reached US$ 1.41 Billion in 2021.
  • Real-world evidence (RWE) refers to clinical evidence about the use and potential benefits or risks of medical products via real-world data (RWD).
  • Real-World Evidence Solutions Market Trends:
    The growing demand for RWE solutions to get precise and clear information about the safety and efficacy of new products represents one of the key factors driving the market.

Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients

Retrieved on: 
Thursday, October 20, 2022
CAP, Physician, CA, Psoriasis, ISO, PX, CLIA, Population, Conference, Machine learning, Patient, Precision medicine, Certification, MATCH, Decision-making, Doctor of Philosophy, MD, CEO, Health, United, GLOBE, Comorbidity, Veni, vidi, vici, Biomarker, Poster, Medical device, Pharmaceutical industry, Medical imaging

These data validate the willingness of physicians to incorporate Mind.Px test results into their biologic decision making for psoriasis patients as well as demonstrate improved patient outcomes when the test reports were followed.

Key Points: 
  • These data validate the willingness of physicians to incorporate Mind.Px test results into their biologic decision making for psoriasis patients as well as demonstrate improved patient outcomes when the test reports were followed.
  • [ii] Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percent [iii] , leading to trial-and-error patient treatments and increased healthcare costs.
  • Mind.Px is a predictive test used to improve management of psoriasis patients and allows physicians to prescribe biologic drugs with >92 percent positive predictive value.
  • This is a key milestone in demonstrating the clinical utility of the test and, ultimately, incorporation into clinical practice.

Base Healthcare Launches Innovative Platform for Men with Testosterone Deficiency

Retrieved on: 
Tuesday, October 18, 2022
Heart rate, Cardiovascular disease, Testosterone, Smartphone, ATT, Sleep, Hypogonadism, Man, Blood pressure, NASH, Exercise, Obesity, Consumers United for Evidence-based Healthcare, Fatty liver disease, DEXA, Type 2 diabetes, GLOBE, FDA, Comorbidity, Patient, Pharmaceutical industry, Medical device

The digital-forward platform will offer a convenient way for men to access Adequate Testosterone Therapy (ATT), certified-clinicians, and patient-centered health coaching.

Key Points: 
  • The digital-forward platform will offer a convenient way for men to access Adequate Testosterone Therapy (ATT), certified-clinicians, and patient-centered health coaching.
  • Base Healthcare is initially focused on the treatment of hypogonadism or low testosterone and will offer additional services and supplements for men in early 2023.
  • Base Healthcare chose the focus of low testosterone because it is one of the biggest blind spots in medicine today.
  • Base Healthcare is a mens virtual health platform focusing on foundational health and hormone optimization using testosterone therapy and patient-centered health coaching.

Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

Retrieved on: 
Friday, October 7, 2022
COVID-19, Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, MSD, UKRI, NHS, National Institute, Antipyretic, HR, UK Research and Innovation, Omicron, Disease, Hospital, National Institute for Health Research, Medicine, Fatigue, Risk, MHRA, Merck & Co., Population, Early, Policy, Severe acute respiratory syndrome coronavirus 2, COVID, Immunity, Particle-size distribution, NYSE, Patient, Mortality, Community, NIHR, University, COVID-19, Virology, Novel, Research, Safety, BCI, CI, Death, MRK, Trial of the century, Comorbidity, Cough, Pharmaceutical industry, Health insurance, Merck, Clalit Health Services

Additionally, Merck is reporting results from a recent carcinogenicity study in transgenic mice, which demonstrated that LAGEVRIO was not carcinogenic at any dose tested.

Key Points: 
  • Additionally, Merck is reporting results from a recent carcinogenicity study in transgenic mice, which demonstrated that LAGEVRIO was not carcinogenic at any dose tested.
  • Of them, 19,868 patients were eligible for LAGEVRIO therapy; 1,069 (5%) patients received at least one dose of LAGEVRIO.
  • Global access has been a priority for Merck and Ridgeback since the inception of their LAGEVRIO collaboration.
  • Since licensed by Ridgeback, all funds used for the development of LAGEVRIO have been provided by Merck and Ridgeback.

Spatially Health Launches Digital Health 90-Day Equity Equalizer Pilot

Retrieved on: 
Tuesday, October 4, 2022
Data collection, ZIP, YouTube, ACO, Technology, LinkedIn, Intelligence, Compliance, Comorbidity, Twitter, MCO, Instagram, Acos, Health care, Program, Method, Health equity, Risk management, Patient, MA, Organization, CMS, Population, Medical device, Medical imaging, Health, Spatial epidemiology

MIAMI, Oct. 4, 2022 /PRNewswire-PRWeb/ -- Spatially Health, a cloud-based, technology company focused on pioneering new methods in geospatial analytics and location intelligence to better understand and improve social determinants of health (SDOH), has announced the launch of its 90-day pilot program for risk-based organizations including ACOs, MCOs, and MA organizations.

Key Points: 
  • The Spatially Healthy Equity Equalizer Platform gives providers 90-day access to Spatially's essential data intelligence, including prioritized interventions by SDOH risks, and cost savings.
  • Benefits of the Equity Equalizer Pilot Program for organizations:
    Prioritizing SDOH interventions and their impact on maximizing cost savings.
  • As health equity becomes a top priority, risk-based organizations benefit from including equity measurements in their ongoing risk management.
  • For more information on Spatially Health, visit http://www.SpatiallyHealth.com or connect with Spatially Health on LinkedIn , Twitter, Instagram , and YouTube .

New Cadence Data Show Improved Outcomes for Heart Failure Patients

Retrieved on: 
Monday, October 3, 2022
General Health, Health, Cardiology, Duke University Hospital, Journal of Cardiac Failure, Technology, Health, GDMT, III, CHF, Heart, RPM, Quality of life, Program, Data science, Journal, Patient, Heart failure, Hypertension, Comorbidity, Cardiology, Duke University Medical Center Patient Rapid Transit, Pharmaceutical industry, Medical imaging, Medical device, Cadence

Today, health technology company Cadence unveiled initial clinical data from patients with heart failure with reduced ejection fraction (HFrEF) showing improved clinical outcomes, including increased use of guideline-directed medical therapy (GDMT).

Key Points: 
  • Today, health technology company Cadence unveiled initial clinical data from patients with heart failure with reduced ejection fraction (HFrEF) showing improved clinical outcomes, including increased use of guideline-directed medical therapy (GDMT).
  • Presented as an oral abstract at the 2022 Heart Failure Society of Americas (HFSA) Annual Scientific Meeting, Cadences medical and data science team presented the results of a study of 97 comorbid patients with advanced heart failure (New York Heart Association Class II and III).
  • Daily monitoring allows us to safely and effectively titrate patients GDMT, which has historically been incredibly difficult for clinicians caring for heart failure patients at home.
  • Since publication of the HFSA abstract, Cadence data has also revealed improved clinical outcomes for congestive heart failure patients, including a 50% reduction in frequency of patients visiting the emergency room.1 While 98% of Cadences patients say they are receiving the highest quality medical care in a way that is easy for them to understand.

SAGE Journals Publishes New Data Revealing NEXGEL’s SilverSeal Hydrogel Dressing Improves Postsurgical Scarring

Retrieved on: 
Monday, October 3, 2022
NASDAQ, Scar, Burns, Research, Pain, Foot, Patient, Ageing, SAGE, Ankle, Comorbidity, GLOBE, Pharmaceutical industry

LANGHORNE, Pa., Oct. 03, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that SAGE Journals’ Scars, Burns and Healing publication, a peer-reviewed journal that focuses on scar and burns research, has published new data from a study evaluating the impact of NEXGEL’s SilverSeal® hydrogel dressing on postoperative scarring and complications. The results demonstrated significant scar improvement in patients treated with SilverSeal.

Key Points: 
  • SilverSeal was used post-surgery as an antimicrobial dressing to evaluate its ability to aid in the healing process.
  • 40 foot and ankle patients (aged 32 to 66) were included in the double-blind, randomized study with 20 patients in each group.
  • Postoperatively, the treatment group was given a SilverSeal hydrogel dressing, and the control group was treated with a standard petroleum-based dressing.
  • We found that patients treated with NEXGELs SilverSeal hydrogel dressing experienced significantly less negative symptoms and regained their skin functionality quickly.

Lionrock Adds Ketamine Assisted Psychotherapy Program to State-of-the-Art Treatment Offerings for Substance Use Disorder

Retrieved on: 
Thursday, September 29, 2022
Science, Neurology, Telemedicine, Virtual Medicine, Research, Pharmaceutical, Managed Care, Health, Mental Health, Ketamine, IOP, SUD, COVID-19, Suds, Risk, Brain, Joint, Psychotherapy, Intensive outpatient program, Program, Patient, CEO, Comorbidity, CDC, KAP, Research, Medicine, Multimedia, Joint Commission, Depression, Pharmaceutical industry, Lionrock

Lionrock , the inventor of telehealth services for substance use disorders (SUDs) treatment and recovery services in the United States, today announces its Ketamine Assisted Psychotherapy (KAP) pilot program, the latest treatment method to be added to the companys state-of-the-art, research-based care offerings.

Key Points: 
  • Lionrock , the inventor of telehealth services for substance use disorders (SUDs) treatment and recovery services in the United States, today announces its Ketamine Assisted Psychotherapy (KAP) pilot program, the latest treatment method to be added to the companys state-of-the-art, research-based care offerings.
  • View the full release here: https://www.businesswire.com/news/home/20220929005227/en/
    Lionrock announces a progressive new Ketamine Assisted Psychotherapy (KAP) treatment program used in a supervised setting that assists in both substance use disorder (SUD) recovery and continued recovery.
  • The pilot program will allow us to optimize ketamine assisted psychotherapy treatment and find the most efficient and effective way to deliver this care at scale.
  • With the launch of our Ketamine Assisted Psychotherapy (KAP) program, Lionrock is again at the cutting edge of SUD treatment.